




SPACS 2021

CANCER CAPITAL CORP
Rank 13 of 17





SPACS 2021

CANCER CAPITAL CORP
Rank 13 of 17

The relative strengths and weaknesses of CANCER CAPITAL CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CANCER CAPITAL CORP compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 24% points. The greatest weakness of CANCER CAPITAL CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 147% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,014%, being 293% points below the market average of -721%.

Input Variable	Value in 1000 USD
Assets, Current	0.70
Assets, Non-Current	0
General And Administrative Expense	14
Liabilities, Current	333
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-17
Other Revenues	0
Professional Fees	0

Output Variable	Value in 1000 USD
Assets	0.70
Liabilities	333
Expenses	14
Revenues	0
Stockholders Equity	-332
Net Income	-31
Comprehensive Net Income	-31
Economic Capital Ratio	-1,014%